Introduction
The very late activation antigens (VLA)' are a set of human cell surface glycoproteins (1) (2) (3) (4) (5) that have been implicated as receptors for extracellular matrix proteins (6, 7) . They were initially named "very late activation antigens" because after long-term T cell activation, the ,8-chain increases in amount and additional a-subunits appear. More specifically, T cells in the resting state express a 1 30 ,000-Mr chain that is recognized by the mAb A-lA5 and is termed the /3-chain (4) . With long term mitogen-or mixed lymphocyte reaction (MLR)-activation, VLA increases in amount and the ,3-chain forms noncovalently linked heterodimers with either a 200,000-Mr (a') or a 165,000-M, (a2) glycoprotein. The a'/3 complex is termed VLA-1 and the a 2# complex is termed VLA-2. Studies of the cellular distribution of VLA molecules show that the common 1 30,000-Mr ,B chain is present upon many types of resting and activated cells. Resting platelets also express VLA-like glycoproteins with 140,000-and 165,000-Mr chains that can be immunoprecipitated by VLA-specific monoclonal antibodies (2, 8) . The VLA family includes at least three more heterodimers, VLA-3, VLA-4, and VLA-5 (5). The VLA-3 and VLA-5 heterodimers have been recently found to be similar or identical to receptors for fibronectin and laminin (6) .
Platelet surface proteins have been identified and analyzed by a variety of physicochemical techniques, including O'Farrell isoelectric-focusing SDS-PAGE two-dimensional (2D) gel analysis (9) (10) (11) , and nonreduced-reduced 2D diagonal SDS-PAGE (10, 12, 13) . In this study we have isolated VLA from platelets by immunoprecipitation with VLA-specific mAbs and used these techniques to identify the immunoprecipitated molecules. These experiments show that these platelet molecules are composed of three proteins previously characterized as platelet glycoproteins GPIa, GPIc, and GPIIa and provide evidence that in detergent solution there exists mixed heterodimers ofGPIIa with GPIa, and GPIIa with GPIc. Those platelet glycoproteins share physicochemical properties with lymphocyte VLA-2 and VLA-3. GPIIa is homologous to the VLA 3-chain, GPIa to the VLA ac2-chain and GPIc to a different VLA a chain.
Methods
Cell preparation. Peripheral blood mononuclear cells (PBMs) were obtained by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) density gradient centrifugation (14) and washed three times with RPMI 1640. These were further processed by passage through a nylon wool (NW) column (15) to yield NW T-enriched cells (T cells) before iodination. The T cell leukemia Mo-l (16) was obtained from the American Type Culture Collection (Rockville, MD; ATCC, CRL 8066) and passaged in Iscove's Modified Dulbecco's Media supplemented with 10% fetal calf serum (FCS) . The neuroblastoma cell line SK-N-SH was obtained and cultured as previously described (17, 18) .
Platelet preparations. 30 ml of venous blood was obtained from aspirin-free healthy individuals and mixed with 5 ml acid-citrate dex-trose ( 13.5 g citric acid, 25 g Na citrate, 20 g dextrose per liter, pH 4.5, ACD) and centrifuged at 180 g for 15 min at 22°C to yield platelet-rich plasma (19) . The platelets were then washed twice by suspension and centrifugation in Tris-buffered saline (TBS), pH 6.5, at 1,000 g for 15 min and then iodinated.
Radiolabeling. Lymphocytes were surface iodinated by a modification of the method of Baur et al. (20 (19) , and mAb 12F1 which recognizes VLA-2 (8) were produced by us. The VLA-2 specificity of 12F1 appears to be due to its reaction with determinants on the a2-chain.
Extraction and immunoprecipitation. Cells were lysed with nonionic detergent and immunoprecipitated as previously described (8, 23, 24) . Platelets were suspended in 1.5 ml TBS pH 7.4 to which 1. Platelet radioligand-binding studies. Platelet-rich plasma was prepared from ACD-collected whole blood, and platelets were pelleted and then gel filtered on Sepharose CL-2B at room temperature in divalent cation-free Tyrode's buffer, pH 7.2, containing 2% bovine serum albumin and 0.1% glucose (TBG) as previously described (26) .
They were then reacted (1 X 107 platelets/ml I mM CaCI2, 1 AM PGE,) for 60 min with dilutions of chloramine-T radioiodinated DEAE-cellulose purified monoclonals A-1AS or 12F1 (3.33 x 10" -1 x 10-8 M). Cell-bound ligand was separated from free ligand by centrifugation of platelets through 20% sucrose in TBG and measured as previously described (26) . Ligand binding was assessed, and results were analyzed by the method of Scatchard (27) . Nonspecific binding was determined by performing binding studies in the presence of a 50-100-fold excess of unlabeled ligand and was found to be < 5% of total binding. The line that best fits the data was generated by least squares linear regression.
Sequential nonreduced-reduced SDS-PAGE. Immunoprecipitates were prepared and processed as described above except they were not reduced and one-dimensional electrophoresed using 6% or 8% SDS-PAGE tube gels. After electrophoresis in the first dimension the tube gels were equilibrated with SDS-PAGE loading buffer containing 5% 2-mercaptoethanol (2-ME) for 15 min at 22°C and then run in the second dimension on a 8% slab SDS-PAGE, processed, and autoradiographed as described above for one-dimensional SDS-PAGE.
O'Farrell 2D-PAGE. 2D-PAGE was carried out after the method of O'Farrell (28) as previously described (8, 23) . Samples were eluted from the SAC or Sepharose immunoadsorbents by incubation with 8 M urea, 5% 2-ME for 60 min at 22°C and applied to prefocused 6% acrylamide tube gels with 10 mM phosphoric acid and 50 mM Tris electrode solutions, and focused for 10 h at 1,000 V. The gels were then equilibrated with SDS-PAGE diluent buffer and run on 8% SDS-PAGE in the second dimension and processed as described above for ID SDS-PAGE.
Neuraminidase digestion. Neuraminidase (isolated from Clostridia perfringens, Sigma Chemical Co.) was added to iodinated lysates at 0.08 U/ml and incubated at 37°C for 60 min and then immunoprecipitates prepared.
Results
One-dimensional SDS-PAGE ofplatelet molecules precipitated with VLA-specific MAbs reveals multiple chains. The VLAspecific mAb A-lA5 was used to immunoprecipitate nonionic detergent extracts of lactoperoxidase cell surface iodinated platelets, SK-N-SH neuronal cells and the T cell leukemia line Mo-1 and immunoprecipitated molecules analyzed by SDS-PAGE (Fig. 1) . The SK-N-SH (lane 1) and leukemic T cell line Mo-1 (lane 2) preparations contained the three bands of 180,000 Mr (a'), 160,000 Mr (a2) and 130,000 Mr (O3) chains, which are characteristic of a mixture of VLA-l (a',@ heterodimer) and VLA-2 (a2'# heterodimer) as previously described (4, 23) . The platelet A-lA5 precipitate (lane 3) contained two bands of 165,000 Mr and 145,000 Mr that were of nearly equal radioactive intensity. Similar results have been obtained with platelets from 20 different donors. These chains were of slightly greater molecular weight than the VLA a2 and 13 chains isolated from the T cell line. Previous small differences ofVLA have been observed that disappear on removal of the carbohydrate (4) . Platelets lack the 180,000 Mr VLA al chain. Thus, it appears that the platelet VLA-2 heterodimers comprise a large fraction of the platelet VLA molecules.
The similar one-dimensional SDS-PAGE pattern of the monoclonal antibody precipitated VLA from platelets and other cell types led us to compare immunoprecipitated samples from lymphoid and platelet sources by O'Farrell 2D gel electrophoresis (Fig. 2) . Samples of VLA prepared with mAb A-lA5 from platelets and CEM were analyzed individually ( and GPIb. We sought to determine which of the previously physicochemically characterized platelet membrane glycoproteins comprise the anti-VLA immunoprecipitates. The electrophoretic mobilities of platelet VLA molecules were compared with those of platelet GPIIb and GPIIIa, GP140, and GPIb in nonreduced conditions (Fig. 3 ) and reduced conditions (not shown). Aliquots of nonionic detergent lysates of radioiodinated platelets were immunoprecipitated with A-lA5, 12F1, GPIb-specific AN5 1, GP140-specific S 12, and GPIIb/IIIa-specific mAb 2G12, and the precipitates were examined without 2-ME reduction on ID SDS-PAGE. GPIIb and GPIIIa demonstrated their characteristic migration patterns (13). The VLA chains from platelets (lanes 2 and 3) were clearly different from those ofGPIIb and GPIIIa (lane 5 (Fig. 4) . Lysates were immunoprecipitated with the VLAspecific mAb A-lA5 or the GPIIb/IIIa-specific mAb 2G12. Gels were then run of the A-lA5 precipitate alone (Fig. 4 A) , the 2G12 precipitate combined with the A-lA5 precipitate (Fig. 4 B) , the 2G12 precipitate alone (Fig. 4 D) and the detergent lysate alone (Fig. 4 E) . The identification of the spots corresponding to GPIIba, GPIIIa, GPIa, GPIca and the comigrating GPIIa and GPIba was made by comparison with published gels (8) . Comparing the precipitate of A-lA5 against the internal reference of GPIIb/IIIa precipitated by 2G12 in Fig. 4 B and against the pattern of platelet surface glycoproteins in Fig. 4 E showed the comigration of the 165,000 M, protein seen in the 1D SDS-PAGE with GPIa. Further, the 145,000 M, band seen in 1D SDS-PAGE is seen to resolve into two spots of slightly differing sizes and pIs (145,000 Mr, pl = 4.7 versus 140,000 Mr, pI = 5.1) that comigrate with GPIIa or GPIba, and GPIca, respectively. Repeated experiments resulted in similar, though slightly different pI values (compare Fig. 4 A to Figs. 2 A and 6 A) presumably as a result of the nonequilibrium nature of focusing of high molecular weight proteins and minor differences in experimental conditions. Since the GPIb was shown to be distinct from the VLA molecules (Fig. 2) the data indicates it coincides with GPIIa. These 2D gel electrophoresis results strongly suggested that the VLA molecules precipitated with A-l A5 from platelets are the platelet surface glycoproteins GPIa, GPIc, and GPIIa.
Sequential 2D nonreduced-reduced SDS-PAGE confirms that platelet VLA molecules consist ofGPIIa, GPIa, and GPIc.
The results ofFig. 4 appear to identify the VLA components as major platelet surface glycoproteins. To further support these identifications, the platelet VLA molecules from platelets were analyzed by the method of sequential nonreduced-reduced 2D SDS-PAGE (10, 12, 13). Extracts of radioiodinated platelets were precipitated with mAbs specific for GPIb or VLA, and immunoprecipitates were electrophoresed on SDS-PAGE unreduced in the first dimension. The gel was then reduced and resubjected to SDS-PAGE in the second dimension (Fig.  5) . Comparison of the platelet lysate glycoprotein pattern ( (Fig. 4 C) . Unlike the A-lA5 immunoprecipitate, the 12F1 immunoprecipitate (Fig.  4 C) Quantitation of GPIIa and GPIa molecules on resting platelets. Radioligand binding studies using the mAb A-lA5 and 12F1 were performed to quantitate the number of antibody reactive molecules of GPIIa and GPIa, respectively, on resting platelets. Gel-filtered platelets from four normal male donors were incubated at room temperature for 60 min with varying concentrations of radioiodinated A-lA5 or 12F1. 
Discussion
We have detected glycoproteins antigenically related to VLA upon the surface of resting platelets confirming the observation of Hemler et al. (2) and proceeded to correlate these with previously studied platelet proteins. When analyzed by ID SDS-PAGE, the VLA-2 specific antibody precipitated platelet molecules of two easily distinguishable sizes that, by size and 2D gel electrophoresis correspond with the component chains of the a2# (VLA-2) heterodimer observed on activated T cells and other cell lines. Analysis ofthe VLA fl-chain-specific mAb A-lA5 precipitated platelet glycoproteins by 2D gels demonstrated 3 glycoproteins. The upper band corresponds to VLA a2 chain. The lower molecular weight band seen on ID SDS-PAGE analysis is actually composed of two molecules, a heavily radioiodinated 145,000-Mr chain with a pI of 4 that coelectrophoresed with T cell VLA ,B chain and a weaker 140,000-Mr component with a pl of 5.1 that may be hidden by the larger chain on D SDS-PAGE. This chain's pattern on 2D O'Farrell gels is similar to the VLA a3 or aS chains. However it has been reported that the VLA-3 specific mAb J 143 does not react with platelets (5), indicating it is unlikely GPIc is the VLA a3 chain. The correlation of immunoprecipitation patterns and the apparent identity of the T cell VLA chains with the corresponding platelet proteins suggests strongly that these mAb retain their proven specificities (1, 5, 8) in reacting with the platelet glycoproteins. Detailed study has shown that the A-lA5 mAb reacts with the VLA ,B chain and not with isolated a2 or a3 chains (5) . Thus, we believe the mAb A-lA5 reacts specifically with the 145,000-Mr chain and that the mAb 12Fl reacts specifically with the 1 60,000-Mr chain. Although experiments with dissociated platelet proteins have not been performed, their identical 2D electrophoresis patterns strongly support this conclusion.
Comparison of the positions ofthe three platelet molecules precipitated by VLA mAb A-lA5 by two (4, 5, 8) . Altogether these findings strongly suggest that the platelet GPIIa-GPIa and GPlIa-GPIc molecules exist as heterodimers prior to detergent lysis.
The identification ofthe platelet molecule analogous to the T cell VLA , chain as GPIIa is based upon its location on 2D SDS-PAGE (145,000 Mr and pl of 4.7) and shared reactivity with mAb A-lA5. Similar to the 145,000 Mr VLA (3-chain. GMP-140 has a 140,000 mol wt and a pl of 4.4 (22, 34) and is probably identical with the platelet activation-dependent granule-external membrane (PADGEM) protein (35, 36) . MAb S 12 was originally thought to bind to GPIla (19) (32) , (29, 37) , and the molecules described by Spycher et al. (38) . The platelet granule protein GMP-140 recognized by mAb S12 (22, 34) and by a mAb KC 4 (35, 36) has similar electrophoretic properties as the VLA (3-chain but direct comparison clearly distinguishes each from the other (Fig. 3) .
The recognition that platelet molecules structurally similar or identical to VLA are composed of the platelet components GPIla, GPIa, and GPIc is significant in that it relates two previously separate fields of study. Previous (39) . If molecules should be dissociated by treatment with high pH as has been observed with VLA-2 (4) and the amino acid sequences of the VLA a!2 (40) and the VLA p-chains should apply to GPIa and GPIIa. Also, VLA a!2 should bind CA2' as GPIa does (41) . GPIa, GPIIa, and GPIc constitute three of the six most prominent iodinated surface glycoproteins on platelets; thus they may serve a number of important functions. Little is known of their physiological role, but given the relatedness of VLA to receptors for adhesion molecules one likely possibility is that they contribute to the triggering and adhesion events of platelets. Two ofthe other three prominent platelet membrane glycoproteins include the heterodimer, GPIIb-GPIIIa, which recognizes an Arg-Gly-Asp (R-G-D) sequence of fibrinogen (42, 43) , fibronectin (44, 45) , von Willebrand factor (46, 47) , and vitronectin (48) . By analogy, the GPIIa-GPIa and GPIIaGPIc complexes may also serve receptor functions important in platelet activation or adherence, and the VLA heterodimers on other cell types may have similar roles. Possible ligands are suggested by the recent reports that platelets from a patient lacking GPIa was found to have defective adherence to human collagen type III (49) ; and that a platelet glycoprotein with an electrophoretic behavior similar to GPIa binds to collagen and that binding is inhibited by wheat germ agglutinin, a lectin that binds to GPIa (50) . Thus, the GPIa-IIa dimer on platelets and by analogy VLA-2 on other cell types may be collagen receptors. Another recent study indicates that VLA-3 and VLA-5 proteins act like fibronectin/laminin receptors (6) .
The recognition that platelet glycoproteins GPIIa, GPIa, and GPIc are related or identical to VLA should enhance analysis of their structure and function. MAbs specific to individual platelet VLA glycoproteins will enable the isolation ofindividual platelet proteins. A-lA5 reacts with the common 3-chain of VLA (4), which is identical to platelet GPIIa, and 12Fl binds specifically to the a2-chain of VLA (GPIa) (40) . Other VLA-specific mAb also should be useful, including the mAb J143 (51) recently shown to react with VLA-3, which may react specifically with GPIc. These VLA specific mAbs to cell surface receptors may prove to be useful probes of the physiologic role of GPIIa and GPIa in platelet activation and adherence.
Note added in proof M. E. Hemler (personal communication) has recently found that platelets bear VLA-5 and a new form of VLA, VLA-6, but do not bear VLA-3. This suggests that GPIc corresponds to the VLA a5 or a6 chain.
